DelveInsight's DUB Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...
Lymphoma represents a spectrum from indolent to aggressive disease; prognosis and management should be individualized by biologic behavior and owner goals. Avoid reflexively applying a single protocol ...
The FDA granted orphan drug designation to CTD402 for relapsed or refractory T-cell acute lymphoblastic leukemia and ...
SurvivorNet on MSN
Targeted drug Epkinly is suddenly front & center in lymphoma care: Here’s what patients need to know
The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...
Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...
The rate of young people dying from cancer is dropping across the United States, but death rates from one type of cancer have ...
Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.
On January 16, 2026, the U.S. Food and Drug Administration (FDA) released a statement saying they had granted full approval ...
Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results